Vyriad, Inc. Raises $29.5M in Series B Funding Led by Renowned Genetics Entrepreneur
Vyriad, a clinical-stage biotechnology firm focused on oncological virus therapies, secured $29.5M in funding led by Harry Stine of Stine Seed Farms. This investment increases Vyriad's total funding since 2015 to over $100M. The company aims to develop safe, effective oncolytic viruses to treat cancer, leveraging high-throughput screening methods. Dr. James Hampton, a genetics expert, joins Vyriad's Board as part of this funding round. Vyriad has an ongoing collaboration with Regeneron (NASDAQ: REGN) to explore new oncolytic treatments.
- Secured $29.5M in new funding, increasing total capital to over $100M since 2015.
- Continued collaboration with Regeneron enhances research capabilities and potential treatment developments.
- None.
ROCHESTER, Minn., May 17, 2022 /PRNewswire/ -- Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced
"In my initial discussions with Mr. Stine, I was amazed to learn that Vyriad's approach for developing safe, effective, cancer-targeted oncolytic viruses closely mirrors the Stine Seed model of high throughput screening, selection and commercialization of novel soybean and corn strains," observed Vyriad Co-Founder and CEO, Dr. Stephen Russell. "Leveraging these approaches, Vyriad aspires to become a powerhouse for the generation and partnered commercialization of high performing safety-modified oncolytic viruses that, used alone or in combination with established therapies, can eliminate cancer without significant off-target effects or untoward toxicities."
Dr. James Hampton, Professor Emeritus at Buena Vista University and leading genetics and genomics expert, has joined Vyriad's Board of Directors in conjunction with the financing. Dr. Hampton commented, "Based on its unique technology platforms, broad patent coverage, and data driven approach to developing superior genotypes, Vyriad displays striking similarities to the approach I have seen Mr. Stine deploy in developing the world's premier agricultural germplasm. The high throughput genetics model that has worked so well in feeding the world, will be equally successful in developing oncolytic virus therapies that offer novel and effective treatments for cancer."
About Stine Seed Farms, Inc.
Stine Seed Farm, Inc., founded by Harry H. Stine and headquartered near Adel, Iowa, is focused on developing and marketing the world's best-performing corn and soybean seed through its retail arm, Stine Seed Company. Stine Seed Farm, Inc., operates the industry's largest corn and soybean breeding and development programs, advancing and testing nearly 1 million unique soybean varieties and more than 100,000 preliminary corn hybrids annually. For nearly five decades, Stine's soybean research program has been regarded as the soybean genetics supplier of choice to the seed industry.
About Vyriad, Inc.
Vyriad is a clinical-stage company developing oncolytic virus therapies for the treatment of cancers. Founded by scientists at Mayo Clinic and the University of Miami, Vyriad is currently working with various virus platforms, programming them to selectively kill cancer cells and ignite antitumor immune responses to complete and sustain the process of tumor destruction. In 2019 Vyriad and Regeneron (NASDAQ: REGN) established a broad-based strategic agreement to discover and develop new oncolytic virus treatments that leverage Vyriad's vesicular stomatitis virus (VSV) platform, as well as Regeneron's unmatched antibody discovery capabilities. Vyriad's lead clinical stage VSV asset, Voyager-V1, is being evaluated in ongoing Phase 1-2 clinical trials addressing multiple cancer types, alone or in combination with Regeneron's PD-1 inhibitor Libtayo® (cemiplimab-rwlc).
Vyriad is privately held and based in Rochester, Minnesota. Its 25,000 square foot facility on the Rochester Technology Center campus includes offices, state of the art research laboratories, a GMP manufacturing facility and support systems for multicenter oncolytic virus therapy clinical trials. For more information, visit www.vyriad.com.
Contacts:
Media Relations:
mediarelations@vyriad.com
Investor Relations:
Barb Duckett
(507) 289-0944
bduckett@vyriad.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/vyriad-inc-raises-29-5m-in-series-b-funding-led-by-renowned-genetics-entrepreneur-301548372.html
SOURCE Vyriad, Inc.
FAQ
What funding did Vyriad announce on May 17, 2022?
How does Vyriad's funding impact its collaboration with Regeneron (REGN)?
Who joined Vyriad's Board of Directors following the recent funding?
